Various regenerative cell therapy launches around the world is estimated to contribute to the global regenerative medicine market growth. Besides, awareness among population regarding the available stem cell procedures and regenerative therapies effectively curing cancer and diabetes is increasing.
Further, government is taking initiatives towards the regenerative medicine market growth by research funding which is estimated to contribute to the market escalation during the forthcoming years.
Regenerative Medicine implements biomedical approaches for cellular regeneration by biologically active molecules administered alone or as a secretion by infused cells. These regenerative processes are carried out for transplantations and in-vitro organ growth. Regenerative medicines hold unique applications in the research of extracellular matrix (three dimensional network of extracellular macromolecules) and cord blood (blood in the placenta).
Increasing incidences of chronic oncogenic diseases such as cancer with an estimated new cases of 18.1 million in 2018 as per International Agency for Research on Cancer (IARC), is anticipated to display rapid growth in application of regenerative medicines in the upcoming years. Additionally, increasing application of regenerative medicines to treat auto-immune hepatitis, is expected to back the rampant growth in the upcoming years. Moreover, government initiatives to eliminate chronic diseases is anticipated to aid market growth over the years. For instance, World Health Organization (WHO) launched an initiative to eliminate hepatitis completely by 2030. Furthermore, Regenerative medicines comprising blood stem cell implants can be used to restore healthy bone marrow in patients with leukemia. Besides, experiments in the gene therapy segment to explore benefits for various other medical applications, is expected to propel considerable growth in the regenerative medicines market in the upcoming years.
Additionally, rising geriatric population across the globe holds immense opportunities for regenerative medicines in the upcoming years. According to World Bank, population aged 65 and above increased from 7.64% in 2010 to 8.926% of the overall population in 2018. Moreover, change in climatic conditions and increase in sedentary lifestyles has led to drastic demographic changes in developed and developing countries, resulting in growing number of disease cases associated with aging. This aspect is attributed to contribute considerably to the regenerative medicines market growth across the globe.
The patient pool suffering from diabetes is expanding with growing aging population. The International Diabetes Federation reported that approximately 425 million adults (20-79 years) were living with diabetes in 2017 which is estimated to increase to 629 million by 2045.Regenerative Medicines application in insulin replacement and pancreatic islet regeneration in diabetic patients is envisaged to boost the market significantly during the forthcoming decade. DOWNLOAD SAMPLE REPORT HERE
The Global Regenerative Medicines Market is segmented region wise into 5 major regions comprising of North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Crohn’s disease is a highly morbid condition which is notoriously difficult to treat resulting in patients left to cycle through immune-suppressives fraught with risk of opportunistic infection and multiple perianal procedures laden with risk of incontinence. Crohn’s disease is an auto-immune disease affecting around 5 million people per year in North America. However, regenerative medicines have significantly impacted this disease’s treatment market by it’s ability to use one’s own tissue to restore a healthy state.
The market in North America is projected to garner an estimated revenue of USD 78.52 Billion by end of the forecast period. Additionally, the market in North America region is expected to achieve a CAGR of 19.02% by 2027 as compared to previous year. The Asia Pacific market is expected to witness highest growth rate of CAGR of 19.71% over the forecast period. The rising urban population across the region on account of rising employment opportunities has resulted in an increase in healthcare spending which is consequently propelling the regenerative medicines market. High air pollution levels across the countries of China, India, South Korea and Japan, have resulted in emergence of rare oncogenic and non-oncogenic diseases. The expansion of application range of regenerative medicines in treating such diseases is projected to contribute considerably to the market growth over the forthcoming years.
The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
The global regenerative medicines market is bifurcated by technology into gene therapies, cellular therapies, exosome therapeutics and tissue engineering where in cellular therapies segment is further segmented into cellular immunotherapies, stem cell therapies, therapeutics utilizing, differentiated cell types and direct cell reprogramming.
Among these segments, the cellular therapies segment is projected to lead and is expected to occupy a global market share of 47.60% by 2027, while growing at a CAGR of 18.88% during the forecast period. Increased investment through government regulations is anticipated to foster the market growth during the forecasted period. Government of Canada in 2019 has invested US$18 million in regenerative medicine and cellular therapies research through the Stem Cell Network (SCN). This has resulted in reduced steps for clinical trials of these medicines for conditions such as diabetes, cardiovascular disease, blood cancers and septic shock.
Furthermore, according to World Bank, more than 2300 clinical trials on gene therapy were carried out in 2017. This has led in attainment of higher information about the potential applications and working of gene therapy. Besides, gene therapy is becoming a significant sector in bioscience industry research and can be produced on a commercial-scale which is projected in further expand its application range.
The global Regenerative Medicines market is segmented by source into autologous and allogeneic, out of which the autologous segment held the largest market size in 2018, and is estimated to grow significantly throughout the forecast period. Companies are focusing on the development of autologous and allogeneic therapies to treat cancer by joining venture with different organizations which is estimated to foster the global regenerative medicine market.
The global Regenerative Medicines market is segmented by application into cardiovascular, oncology, dermatology, musculoskeletal, hematology & immunology, neurology & others, out of which the oncology segment held the largest market size in 2018 and is estimated to grow significantly throughout the forecast period. Cancer immunotherapy actuates, substitutes, engineers or restores the immune system in order to fight cancer. It is the most frequently used and promoted form of regenerative medicine.
The global regenerative medicines market is bifurcated by end-users into hospitals, clinics, ambulatory surgical centers and others. Among these segments, the hospitals segment is projected to lead and is expected to occupy a global market share of 51.38% by 2027, while growing at a CAGR of 18.86% during the forecast period. Hospitals around the world are investing in research and development and providing treatment which cannot be achieved through traditional methods.
Key factors driving the growth of Regenerative Medicines market includes increasing incidences of cancer, cardiovascular diseases & diabetes, rising geriatric population and upsurge in R&D activities. Initiatives by market players to raise funds for R&D of regenerative medicine is anticipated to support growth of the regenerative medicine market. In addition, companies are collaborating to enhance their R&D capabilities to develop and commercialize innovative therapies to ensure their availability to the local and global customer’s base.
Further, between 2006 and 2016 the population age 60 and over increased 36% from 50.7 million to 68.7 million. Increasing geriatric population with immunologic, ophthalmic and cardiovascular diseases is anticipated to contribute to the positive growth of the regenerative medicine market around the world. Increasing number of diabetes patients worldwide is further estimated to contribute to the global regenerative medicine market. According to International Diabetes Federation, Diabetes caused at least USD 727 billion dollars in health expenditure in 2017. Besides, a large number of people with diabetes were between 40 and 59 years of age and it caused 4 million deaths in 2017.
High cost of treatment among lower income people in developing countries is estimated to play as the key factor in limiting the growth of global regenerative medicine market over the forecast period. According to stem cell journal 2017, over the past 20 years, there have been multiple administrative restrictions placed on high cost therapies in U.S. This in turn is limiting access and utilization, despite the innovative therapies’ potential or proven clinical and societal benefits.
Additionally, rapidly increasing hospital inpatient costs and hospital stays are also contributing to limiting the market consequently restraining the growth of global regenerative medicine market across the under-developed regions across the world.
Smith & Nephew Plc., Sangamo, Integra LifeSciences Corporation, Novartis, Stryker Corporation are some of the leading players in the global Regenerative Medicines market.
Sangamo Therapeutics is a clinical stage biotechnology company offering products in segments that include Gene Therapy, Genome Editing, Cell Therapy and Gene Regulation. The company’s product pipeline includes Hemophilia, Lysosomal Storage Disorders (lsds), hemoglobinopathies, central nervous system and HIV.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization